Evidence map›Paper›PMID 29461939›Full record

ArticleMicrobial drug resistance (Larchmont, N.Y.)2018

Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen.

Nagendran Tharmalingam, Rajmohan Rajmuthiah, Wooseong Kim, Beth Burgwyn Fuchs, Elamparithi Jeyamani, Michael J Kelso, Eleftherios Mylonakis

Open access · greenAbstract read
In one paragraph

Article in Microbial drug resistance (Larchmont, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hydroquinones Inhibit Biofilm Formation and Virulence Factor Production inInternational journal of molecular sciences · 2022
    Article
  6. Antibiofilm Activities of Cinnamaldehyde Analogs against UropathogenicInternational journal of molecular sciences · 2022
    Article
  7. Protective Immunity againstInternational journal of molecular sciences · 2022
    Article
  8. Review
  9. Review
  10. Frontiers in nutrition · 2020
    Review
  11. Frontiers in cellular and infection microbiology · 2020
    Article
  12. Article
  13. Observational
  14. Article
  15. Herring Oil and Omega Fatty Acids InhibitFrontiers in microbiology · 2018
    Article
  16. Frontiers in microbiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Nagendran Tharmalingam1 Infectious Diseases Division, Department of Medicine, Warren Alpert Medical School of Brown University , Rhode Island Hospital, Providence, Rhode Island.
Rajmohan Rajmuthiah1 Infectious Diseases Division, Department of Medicine, Warren Alpert Medical School of Brown University , Rhode Island Hospital, Providence, Rhode Island.
Wooseong Kim1 Infectious Diseases Division, Department of Medicine, Warren Alpert Medical School of Brown University , Rhode Island Hospital, Providence, Rhode Island.
Beth Burgwyn Fuchs1 Infectious Diseases Division, Department of Medicine, Warren Alpert Medical School of Brown University , Rhode Island Hospital, Providence, Rhode Island.
Elamparithi Jeyamani2 Massachusetts General Hospital , Department of Genetics, Harvard Medical School, Boston, Massachusetts.
Michael J Kelso3 Illawarra Health and Medical Research Institute and School of Chemistry, University of Wollongong , Wollongong, New South Wales.
Eleftherios Mylonakis1 Infectious Diseases Division, Department of Medicine, Warren Alpert Medical School of Brown University , Rhode Island Hospital, Providence, Rhode Island.
Brown University · USMassachusetts General Hospital · USUniversity of Wollongong · AU

Funding

Technical Mother Machine CoreP01AI083214 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI David C Hooper · 2009 to 2026
$39.4M
NIAID NIH HHS P01 AI083214
6 · The paper itself

Abstract

There is an urgent need for the discovery of effective new antimicrobial agents to combat the rise of bacterial drug resistance. High-throughput screening (HTS) in whole-animal infection models is a powerful tool for identifying compounds that show antibacterial activity and low host toxicity. In this report, we characterize the activities of four novel antistaphylococcal compounds identified from an HTS campaign conducted using Caenorhabditis elegans nematodes infected with methicillin-resistant Staphylococcus aureus (MRSA). The hit compounds included an N-hydroxy indole-1, a substituted melamine derivative-2, N-substituted indolic alkyl isothiocyanate-3, and p-difluoromethylsulfide analog-4 of the well-known protonophore carbonyl cyanide m-chlorophenyl hydrazone. Minimal inhibitory concentrations (MICs) of the four compounds ranged from 2 to 8 μg/ml against MRSA-MW2 and Enterococcus faecium and all were bacteriostatic. The compounds were mostly inactive against Gram-negative pathogens, with only 1 and 4 showing slight activity (MIC = 32 μg/ml) against Acinetobacter baumanii. Compounds 2 and 3 (but not 1 or 4) were found to perturb MRSA membranes. In phagocytosis assays, compounds 1, 2, and 4 inhibited the growth of internalized MRSA in macrophages, whereas compound 3 showed a remarkable ability to clear intracellular MRSA at its MIC (p < 0.001). None of the compounds showed hemolytic activity at concentrations below 64 μg/ml (p = 0.0021). Compounds 1, 2, and 4 (but not 3) showed synergistic activity against MRSA with ciprofloxacin, while compound 3 synergized with erythromycin, gentamicin, streptomycin, and vancomycin. In conclusion, we describe four new antistaphylococcal compounds that warrant further study as novel antibacterial agents against Gram-positive organisms.

Indexed as

AnimalsAnti-Bacterial AgentsCaenorhabditis elegansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsAnti-Bacterial Agentsantibioticbioactive compoundshigh-throughput screeningisothiocyanatemelamineMRSA infectionN-hydroxy indolesprotonophores

Identifiers

PMID29461939
PMCPMC6001862
OpenAlexW2788566509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.